A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Verstovsek, Srdan, Mesa, Ruben A, Gotlib, Jason, Levy, Richard S, Gupta, Vikas, DiPersio, John F, Catalano, John V, Deininger, Michael, Miller, Carole, Silver, Richard T, Talpaz, Moshe, Winton, Elliott F, Harvey, Jimmie H, Arcasoy, Murat O, Hexner, Elizabeth, Lyons, Roger M, Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Koumenis, Iphigenia L, Sun, William, Sandor, Victor, Kantarjian, Hagop M
Published in The New England journal of medicine (01.03.2012)
Published in The New England journal of medicine (01.03.2012)
Get full text
Journal Article
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms
Hinds, David A., Barnholt, Kimberly E., Mesa, Ruben A., Kiefer, Amy K., Do, Chuong B., Eriksson, Nicholas, Mountain, Joanna L., Francke, Uta, Tung, Joyce Y., Nguyen, Huong (Marie), Zhang, Haiyu, Gojenola, Linda, Zehnder, James L., Gotlib, Jason
Published in Blood (25.08.2016)
Published in Blood (25.08.2016)
Get full text
Journal Article
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A, Vannucchi, Alessandro M, Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N, Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas
Published in Journal of hematology and oncology (29.09.2017)
Published in Journal of hematology and oncology (29.09.2017)
Get full text
Journal Article
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, Srdan, Kantarjian, Hagop, Mesa, Ruben A, Pardanani, Animesh D, Cortes-Franco, Jorge, Thomas, Deborah A, Estrov, Zeev, Fridman, Jordan S, Bradley, Edward C, Erickson-Viitanen, Susan, Vaddi, Kris, Levy, Richard, Tefferi, Ayalew
Published in The New England journal of medicine (16.09.2010)
Published in The New England journal of medicine (16.09.2010)
Get full text
Journal Article
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Cervantes, Francisco, Dupriez, Brigitte, Pereira, Arturo, Passamonti, Francesco, Reilly, John T., Morra, Enrica, Vannucchi, Alessandro M., Mesa, Ruben A., Demory, Jean-Loup, Barosi, Giovanni, Rumi, Elisa, Tefferi, Ayalew
Published in Blood (26.03.2009)
Published in Blood (26.03.2009)
Get full text
Journal Article
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Vannucchi, Alessandro M, Kantarjian, Hagop M, Kiladjian, Jean-Jacques, Gotlib, Jason, Cervantes, Francisco, Mesa, Ruben A, Sarlis, Nicholas J, Peng, Wei, Sandor, Victor, Gopalakrishna, Prashanth, Hmissi, Abdel, Stalbovskaya, Viktoriya, Gupta, Vikas, Harrison, Claire, Verstovsek, Srdan
Published in Haematologica (Roma) (01.09.2015)
Published in Haematologica (Roma) (01.09.2015)
Get full text
Journal Article
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Gupta, Vikas, Mesa, Ruben A, Deininger, Michael W N, Rivera, Candido E, Sirhan, Shireen, Brachmann, Carrie Baker, Collins, Helen, Kawashima, Jun, Xin, Yan, Verstovsek, Srdan
Published in Haematologica (Roma) (01.01.2017)
Published in Haematologica (Roma) (01.01.2017)
Get full text
Journal Article
Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies
Verstovsek, Srdan, Kiladjian, Jean‐Jacques, Vannucchi, Alessandro M., Mesa, Ruben A., Squier, Peg, Hamer‐Maansson, J. E., Harrison, Claire
Published in Cancer (01.06.2023)
Published in Cancer (01.06.2023)
Get full text
Journal Article
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Verstovsek, Srdan, Mesa, Ruben A, Gotlib, Jason, Gupta, Vikas, DiPersio, John F, Catalano, John V, Deininger, Michael W N, Miller, Carole B, Silver, Richard T, Talpaz, Moshe, Winton, Elliott F, Harvey, Jr, Jimmie H, Arcasoy, Murat O, Hexner, Elizabeth O, Lyons, Roger M, Paquette, Ronald, Raza, Azra, Jones, Mark, Kornacki, Deanna, Sun, Kang, Kantarjian, Hagop
Published in Journal of hematology and oncology (22.02.2017)
Published in Journal of hematology and oncology (22.02.2017)
Get full text
Journal Article
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
Harrison, Claire N., Koschmieder, Steffen, Foltz, Lynda, Guglielmelli, Paola, Flindt, Tina, Koehler, Michael, Mathias, Jonathan, Komatsu, Norio, Boothroyd, Robert N., Spierer, Amber, Perez Ronco, Julian, Taylor-Stokes, Gavin, Waller, John, Mesa, Ruben A.
Published in Annals of hematology (01.10.2017)
Published in Annals of hematology (01.10.2017)
Get full text
Journal Article
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Harrison, Claire N, Schaap, Nicolaas, Vannucchi, Alessandro M, Kiladjian, Jean-Jacques, Tiu, Ramon V, Zachee, Pierre, Jourdan, Eric, Winton, Elliott, Silver, Richard T, Schouten, Harry C, Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Lager, Joanne, Shun, Zhenming, Mesa, Ruben A
Published in The Lancet. Haematology (01.07.2017)
Published in The Lancet. Haematology (01.07.2017)
Get more information
Journal Article
Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
Mesa, Ruben A., Scherber, Robyn M., Dueck, Amylou C., Geyer, Holly L.
Published in Mediators of Inflammation (01.01.2015)
Published in Mediators of Inflammation (01.01.2015)
Get full text
Journal Article
HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia
Zhu, Ganqian, Luo, Huacheng, Feng, Yang, Guryanova, Olga A., Xu, Jianfeng, Chen, Shi, Lai, Qian, Sharma, Arati, Xu, Bing, Zhao, Zhigang, Feng, Ru, Ni, Hongyu, Claxton, David, Guo, Ying, Mesa, Ruben A., Qiu, Yi, Yang, Feng-Chun, Li, Wei, Nimer, Stephen D., Huang, Suming, Xu, Mingjiang
Published in Nature communications (29.03.2021)
Published in Nature communications (29.03.2021)
Get full text
Journal Article
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Scherber, Robyn, Dueck, Amylou C., Johansson, Peter, Barbui, Tiziano, Barosi, Giovanni, Vannucchi, Alessandro M., Passamonti, Francesco, Andreasson, Bjorn, Ferarri, Maria L., Rambaldi, Alessandro, Samuelsson, Jan, Birgegard, Gunnar, Tefferi, Ayalew, Harrison, Claire N., Radia, Deepti, Mesa, Ruben A.
Published in Blood (14.07.2011)
Published in Blood (14.07.2011)
Get full text
Journal Article
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Mesa, Ruben A, Vannucchi, Alessandro M, Mead, Adam, Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Jakucs, Janos, Perkins, Andrew, Prasad, Ritam, Mayer, Jiri, Demeter, Judit, Ganly, Peter, Singer, Jack W, Zhou, Huafeng, Dean, James P, Te Boekhorst, Peter A, Nangalia, Jyoti, Kiladjian, Jean-Jacques, Harrison, Claire N
Published in The Lancet. Haematology (01.05.2017)
Published in The Lancet. Haematology (01.05.2017)
Get more information
Journal Article
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Verstovsek, Srdan, Mesa, Ruben A, Livingston, Robert A, Hu, Wilson, Mascarenhas, John
Published in Journal of hematology and oncology (27.07.2023)
Published in Journal of hematology and oncology (27.07.2023)
Get full text
Journal Article